Skip to content


Uptravi (selexipag) is a small molecule pharmaceutical. Selexipag was first approved as Uptravi on 2015-12-21. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. It is known to target prostacyclin receptor. Uptravi's patents are valid until 2036-12-01 (FDA).
Trade Name Uptravi
Common Name Selexipag
Indication pulmonary hypertension
Drug Class
Get full access now